Moleculin Biotech and University of Texas System News

This is selected news for Moleculin Biotech and University of Texas System, which are filed under Sectors / Healthtech and Sectors / Health Systems, respectively.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/19/2022 Moleculin Biotech (MBRX) Moleculin Biotech Inc: 1 director
Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center. The company has three main technologies with six drug candidates. These main ...
researchpool.com
1/10/2018 Orphan Rare Diseases R&D Advancements Increase Novel Therapeutic Options for Drug Development Pipeline
... MBRX), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced it has expanded the Company's development pipeline for the ...
PR Newswire
1/10/2018 Orphan Rare Diseases R&D Advancements Increase Novel Therapeutic Options for Drug Development
... reach US$1.025 Billion by 2025, expanding at a CAGR of 10.9% from 2017 to 2025. Active in the biotech and pharma industry today includes: Moleculin Biotech, Inc. (NASDAQ: MBRX), Global Blood Therapeutics Inc. (NASDAQ: GBT), Pain Therapeutics Inc. (NASDAQ: PTIE), TEVA Pharmaceuticals Industries Limited (NYSE: TEVA), Diffusion Pharmaceuticas Inc ...
PR Newswire
10/18/2017 Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs
... MBRX), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that 14 qualified cancer clinics have requested to participate in its ...
PR Newswire
10/18/2017 Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs
... this year, up 20 percent since January, as many biotechs have the attention of Wall Street ahead of the third-quarter earnings season such as: Moleculin Biotech, Inc. (NASDAQ: MBRX), AmpliPhi Biosciences Corporation (NYSE: APHB), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), Abeona Therapeutics Inc. (NASDAQ: ABEO), Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ...
PR Newswire
10/18/2017 Positive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs
... MBRX), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that 14 qualified cancer clinics have requested to participate in its ...
CNBC